The global nutraceutical space is worth nearly $400 billion today, blending food, pharma, and biotech into one fast-growing industry. India has a strong edge in this sector due to its roots in Ayurveda and a growing wellness-focused market.
Now, Influx Healthtech Limited is stepping into the spotlight with its upcoming IPO. With Rareever Financial Advisors managing the issue and Maashitla Securities as the registrar, the company is ready to go public and tap into the next phase of growth.
For more information, you can refer to the Influx Healthtech Ltd DRHP.
Note: For 50% of the shares, the anchor lock-in period expires 30 days following the actual allocation, and for the remaining part, it ends 90 days later.
Check these details about the company before you get its Influx Healthtech IPO GMP price. Also, see the Influx Healthtech products list.
Let’s explore the key highlights of the Influx Healthtech IPO details.
Track these milestones and get the Influx Healthtech IPO review.
Are you curious about how much they’re aiming to raise? Check the details of Influx Healthtech Limited IPO here.
Here's what Influx Healthtech Limited will do with the raised capital.
Let’s take a closer look at the Influx Healthtech Limited IPO price.
From retail to QIBs, this is how different categories of investors can participate in the Influx Healthtech Limited IPO.
After the allotment is done, your shares will directly reflect in your demat account. Don’t have one yet? This might be the right time to explore top brokers in India who can help you get started.
Also, you can track the Influx Healthtech Limited GMP. Once it hits the market, you must keep an eye on how the share price performs on the exchange.
Before you invest, check out how Influx Healthtech Limited has performed in the past.
Before you look up your allotment status, see the major strengths and risks of Influx Healthtech Limited IPO.
Strengths
The company works on everything from wellness to Ayurveda to nutrition.
Keeps quality tight with FDA approvals, ISO badges, and solid safety checks.
Makes custom products for clients in cosmetics, health supplements, and even pet care.
It has its team that tests and fine-tunes products.
Risks
Operations are concentrated in Palghar, and this makes the business sensitive to regional issues.
A few major customers contribute nearly half the revenue.
No long-term deals with top suppliers add risk to cost and supply stability.
Heavy dependence on the nutraceutical segment may impact growth if industry trends shift unexpectedly.
Influx Healthtech Limited is preparing to go public with its IPO. The company has been active in healthtech, producing veterinary feed supplements, nutritional supplements, homecare, cosmetics, ayurvedic products, finished dosage forms, and more. This IPO marks a new chapter as Influx Healthtech Limited aims to scale up and take on more opportunities. You can check the Influx Healthtech IPO GMP in the news.
Interested in applying for the Influx Healthtech Limited IPO? Click here to get started.
Influx Healthtech Limited is a Mumbai-based nutraceutical and health products manufacturer established in 2020, producing dietary supplements, cosmetics, ayurvedic products, veterinary feed supplements, and APIs. The company holds FDA approvals and ISO certifications with award recognition including Best Nutraceutical Company of the Year. Influx Healthtech reported EBITDA of ₹1,687 lakhs in FY24 with ROE of 49.06% and near-zero debt-equity ratio of 0.01x. Influx Healthtech IPO is an NSE SME issue combining fresh issue of ₹48 crore and OFS of ₹10.56 crore — total ₹58.57 crore — priced at ₹90–₹96 per share, listing on NSE Emerge on June 25, 2025.
